Skip to main content
Conference Fierce Pharma Week in Philadelphia

📍 Philadelphia, PA | September 8–11, 2025 

We’re excited to attend Fierce Pharma Week 2025, a premier gathering of pharma’s most forward-thinking teams across marketing, medical affairs, communications, and commercialization. Meet with the Medlive Solutions team onsite to explore how Medlive is advancing digital education that empowers clinicians, patients, and caregivers. 

Meet with the Medlive Team Onsite

Connect with our team during Fierce Pharma Week to: 

  • Learn more about Medlive Engage: our integrated marketing solution that streamlines peer-to-peer video engagement campaigns. 
  • Explore Medlive Crossfire: our sponsored education model that transforms and accelerates HCP engagement by removing barriers. 
  • Discover how we partner with commercial, medical, and marketing teams to deliver measurable results. 

“At Medlive, we’ve partnered with more than 150 association, society and advocacy groups to deliver trusted digital healthcare education at scale. 

We’re proud to work with more than half of the industry’s leading pharma companies, and excited to bring that experience to Fierce Pharma Week – to join the conversations on how pharma can stay ahead in a rapidly evolving scientific landscape.” 

 – Seth Gordon, General Manager, Medlive Solutions 

Let’s Connect

Interested in a one-on-one conversation? Fill out the Contact Us form on our site to schedule a meeting with the Medlive team during the event. 

Together, we can redefine how medical education supports brand strategy and commercial success. See you in Philadelphia! 

About Medlive

With over 15 years of experience delivering expert-led education, Medlive helps healthcare providers, patients, and caregivers stay current as medical innovation continues to accelerate. In partnership with more than 150 leading advocacy groups and associations, including NORD, KDIGO, and LUGPA, Medlive empowers millions of healthcare providers, patients, and caregivers to make informed medical decisions based on the latest science in oncology, neurology, rare diseases, and other therapeutic areas.

Visit our About Us page for more information.